Polypeptide having pet degradation activity, containing conserved residue
Polypeptides with specific sequences are used to degrade PET plastics into recyclable components, addressing the inefficiencies of existing recycling methods and promoting sustainable PET recycling by producing valuable materials.
Patent Information
- Application Number
- PCT/KR2024/006752
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for recycling PET plastics are imperfect due to quality degradation, carbon neutrality issues, resource depletion, and eutrophication, and there is a need for an environmentally friendly method to decompose PET effectively.
Identification and use of polypeptides with PET degrading activity, specifically through amino acid sequences and motifs, to decompose PET into valuable components like mono(2-hydroxymethyl) terephthalate, terephthalic acid, and ethylene glycol, which can be recycled for polyester production.
Enables efficient and environmentally friendly PET decomposition with high commercial value products, reducing waste and promoting sustainable recycling of PET plastics.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Polypeptide having PET degrading activity, comprising a conserved residue
[0001] The present application relates to a polypeptide having PET decomposition activity.
[0002]
[0003] Over 400 million tons of new plastics are produced annually. As environmental concerns surrounding waste plastics grow, efforts are being made to reduce production through regulations on single-use products and the use of alternative plastics. However, production continues to increase annually. PET, which accounts for less than 10% of all plastics, produces approximately 360 million tons annually. Due to its primary use in single-use products, PET is considered the plastic with the shortest life cycle. Recycling of waste plastics includes mechanical recycling, pyrolysis, and chemical recycling, each of which is either commercialized or in the final stages of research toward commercialization. While each technology offers potential solutions to the waste plastic issue, none of the existing methods are perfect due to the impacts of downcycling on quality, carbon neutrality, resource depletion, and eutrophication of seawater and freshwater.
[0004] To address environmental issues caused by waste plastics, such as microplastics, greenhouse gas emissions, and resource depletion, a series of research results are being published on the use of enzyme-based biological technology to decompose PET, a representative type of plastic.
[0005] [Prior Art Literature]
[0006] (Patent Document 1) US 10851355 B2
[0007]
[0008] The present application relates to a method for identifying a polypeptide having PET (polyethylene terephthalate) decomposition activity, a novel polypeptide having PET decomposition activity identified using the same, a method for decomposing polyesters such as PET using the same, and a method for synthesizing polyesters such as PET by recycling (mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG) obtained through the decomposition.
[0009]
[0010] The purpose of the present application is to provide a method for identifying a polypeptide having PET degrading activity.
[0011] Another object of the present application is to provide a polypeptide having PET decomposition activity.
[0012] Another object of the present application is to provide a composition comprising a polypeptide having PET decomposition activity.
[0013] Another object of the present application is to provide a polynucleotide encoding the polypeptide.
[0014] Another object of the present application is to provide a host cell comprising the polypeptide and / or a polynucleotide encoding the polypeptide; a nucleic acid construct comprising the polynucleotide; and / or a vector comprising the nucleic acid construct.
[0015] Another object of the present application is to provide a method for producing a polypeptide having PET decomposition activity.
[0016] Another object of the present application is to provide a method for degrading a polyester, comprising treating the polyester with at least one of a polypeptide having PET degrading activity; a host cell expressing the polypeptide; and a composition comprising the polypeptide.
[0017] Another object of the present application is to provide a method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA) and / or ethylene glycol (EG), comprising contacting at least one of a polypeptide having PET degrading activity; a host cell expressing the polypeptide; and a composition comprising the polypeptide with a polyester.
[0018] Another object of the present application is to provide a method for producing polyester, comprising a step of synthesizing polyester using MHET, TPA, and / or EG manufactured by the above method.
[0019] Another object of the present application is to provide a use of the polypeptide, a host cell expressing the polypeptide, and / or a composition comprising the polypeptide for PET degradation.
[0020] Another object of the present application is to provide a use of the polypeptide or a composition comprising the polypeptide for reaction with a polyester in the production of mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG).
[0021]
[0022] By using the method of identifying a polypeptide having PET decomposition activity of the present application, it is possible to easily and quickly determine whether any polypeptide has PET decomposition activity without performing a wet experiment. In addition, by using the polypeptide identified in this way, polyesters such as PET can be decomposed in an environmentally friendly manner, and at the same time, high-value decomposition products such as mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG) can be produced, which can be recycled in the production of polyesters such as PET.
[0023]
[0024] One aspect of the present application is a method for identifying a polypeptide having PET degrading activity.
[0025] As one specific example, the method comprises:
[0026] The method comprises the steps of: preparing an amino acid sequence of a polypeptide (predicted polypeptide) expected to have PET decomposition activity; aligning the amino acid sequence of the predicted polypeptide with respect to the reference sequence of SEQ ID NO: 1; and confirming from the alignment result whether the amino acid sequence of the predicted polypeptide has the following characteristics:
[0027] Based on the reference sequence, sequence number 1,
[0028] (1) The residue corresponding to position 62 is F, W or Y;
[0029] (2) The residue corresponding to position 70 is P;
[0030] (3) The residue corresponding to position 81 is I, L, M or V;
[0031] (4) The residue corresponding to position 85 is P;
[0032] (5) The residue corresponding to position 86 is G;
[0033] (6) The residue corresponding to position 94 is I, L, M or V;
[0034] (7) The residue corresponding to position 95 is A or S;
[0035] (8) The residue corresponding to position 96 is A or S;
[0036] (9) The residue corresponding to position 98 is G;
[0037] (10) The residue corresponding to position 99 is F, W or Y;
[0038] (11) The residue corresponding to position 100 is V, L, I or M;
[0039] (12) The residue corresponding to position 101 is V, L, I or M;
[0040] (13) The residue corresponding to position 113 is D, N or E;
[0041] (14) The residue corresponding to position 118 is R, Q or K;
[0042] (15) The residue corresponding to position 135 is Q, R, E or K;
[0043] (16) The residue corresponding to position 157 is D, N or E;
[0044] (17) The residue corresponding to position 165 is G;
[0045] (18) The residue corresponding to position 167 is S, A, N or T;
[0046] (19) The residue corresponding to position 169 is G;
[0047] (20) The residue corresponding to position 170 is G;
[0048] (21) The residue corresponding to position 262 is D, N or E.
[0049] (22) The residue corresponding to position 304 is H, N or Y;
[0050] (23) The residue corresponding to position 322 is W, F or Y; and
[0051] (24) The residue corresponding to position 330 is D, N or E.
[0052] In the above specific example, the amino acid sequence of the predicted polypeptide may be multiple.
[0053] Another aspect of the present application is a polypeptide having PET decomposition activity.
[0054] As a specific example, the polypeptide has PET decomposition activity and, based on the reference sequence SEQ ID NO: 1,
[0055] (1) The residue corresponding to position 62 is F, W or Y;
[0056] (2) The residue corresponding to position 70 is P;
[0057] (3) The residue corresponding to position 81 is I, L, M or V;
[0058] (4) The residue corresponding to position 85 is P;
[0059] (5) The residue corresponding to position 86 is G;
[0060] (6) The residue corresponding to position 94 is I, L, M or V;
[0061] (7) The residue corresponding to position 95 is A or S;
[0062] (8) The residue corresponding to position 96 is A or S;
[0063] (9) The residue corresponding to position 98 is G;
[0064] (10) The residue corresponding to position 99 is F, W or Y;
[0065] (11) The residue corresponding to position 100 is V, L, I or M;
[0066] (12) The residue corresponding to position 101 is V, L, I or M;
[0067] (13) The residue corresponding to position 113 is D, N or E;
[0068] (14) The residue corresponding to position 118 is R, Q or K;
[0069] (15) The residue corresponding to position 135 is Q, R, E or K;
[0070] (16) The residue corresponding to position 157 is D, N or E;
[0071] (17) The residue corresponding to position 165 is G;
[0072] (18) The residue corresponding to position 167 is S, A, N or T;
[0073] (19) The residue corresponding to position 169 is G;
[0074] (20) The residue corresponding to position 170 is G;
[0075] (21) The residue corresponding to position 262 is D, N or E.
[0076] (22) The residue corresponding to position 304 is H, N or Y;
[0077] (23) The residue corresponding to position 322 is W, F or Y; and
[0078] (24) The residue corresponding to position 330 is D, N or E;
[0079] It may be a polypeptide comprising an amino acid sequence.
[0080] As another specific example, the polypeptide having PET decomposition activity comprises motifs of the following general formulae 1 to 5:
[0081] (General formula 1) X1-X2-X3-X4-X5-X6-X7-X8-P:
[0082] where X1 is F, W, or Y; and
[0083] X2 to X8 are any amino acid or absent;
[0084] (General formula 2) X1-X2-X3-X4-PG:
[0085] where X1 is I, L, M or V; and
[0086] X2 to X4 are any amino acid or absent;
[0087] (General formula 3) X1-X2-X3-X4-G-X5-X6-X7:
[0088] X1 is I, L, M or V;
[0089] X2 is A or S;
[0090] X3 is A or S;
[0091] X4 is any amino acid or absent;
[0092] X5 is F, W or Y;
[0093] X6 is V, L, I or M; and
[0094] X7 is V, L, I or M;
[0095] (General formula 4)
[0096] X1-X2-X3-X4-X5-X6-X7-X8-G-X9-X10-X11-GG
[0097] Here, X1 is D, N or E;
[0098] X2 to X8, X9 and X11 are any amino acid or absent; and
[0099] X10 is S, A, N or T;
[0100] (General Formula 5)
[0101] X1-X2-X3-X4-X5-X6-X7-X8-X9
[0102] Here, X1 is W, F or Y; and
[0103] X2 to X8 are any amino acid or absent; and
[0104] X9 is D, N or E.
[0105] As one of the specific examples described above, the polypeptide having the PET decomposition activity is
[0106] (i) WP_109362551.1, SHM40309.1, SDZ16714.1, WP_084434874.1, WP_101366623.1, WP_117215036.1, WP_132413760.1, WP_110567505.1, WP_143590710.1, WP_091553551.1, WP_124822775.1, WP_116180173.1, OGB27210.1, WP_088988822.1, WP_125191182.1, WP_085749752.1, WP_130464304.1, WP_054022242.1, WP_082377728.1, WP_132386942.1, WP_082403176.1, WP_013736455.1, WP_073887759.1, CCH19814.1, WP_141984372.1, WP_155388305.1, WP_039906502.1, WP_137976057.1, WP_132337032.1, WP_093411427.1, WP_075737041.1, WP_139584963.1, WP_088276085.1, PIG53436.1, WP_045318561.1, WP_078759821.1, AEV21261.1, WP_047194864.1, WP_083950838.1, KWV31814.1, ADV92525.1, EOD65379.1, WP_013229249.1, WP_131056699.1, WP_072476921.1, WP_065917710.1, WP_130401777.1, WP_081971423.1, WP_086849962.1, WP_109639600.1, WP_150303381.1, WP_076469402.1, WP_086784246.1, WP_125313231.1, WP_120675340.1, WP_027346283.1, WP_155541557.1, WP_075975245.1, WP_144126986.1, WP_078844206.1, WP_091283529.1, WP_103503499.1, WP_130969140.1, WP_112669767.1, KNX38636.1, GBD22443.1, WP_083302694.1, WP_091084084.1, WP_093954453.1, WP_116813002.1, WP_089021493.1, PWK39581.1, WP_011291330.1, WP_123685830.1, WP_123748612.1, WP_084400763.1, WP_132183354.1, ADV92527.1, WP_014689902.1, WP_093935592.1, RZS34008.1, WP_138709315.1, WP_141569747.1, 1JFR_A, WP_124770494.1, 4WFI_A, WP_143737449.1, WP_080041749.1, CBY05529.1, WP_111700265.1, OKK16161.1, WP_143320421.1, WP_084578793.1, WP_104613137.1, WP_104115406.1, SPF04022.1, WP_119701604.1, WP_120326365.1, PWW60275.1, WP_086668955.1, WP_092528534.1, WP_063729606.1, 3VIS_A, WP_138698985.1, WP_145923095.1, WP_068752972.1, MBA55398.1, WP_123888242.1, WP_083724990.1, WP_044499735.1, WP_051808300.1, WP_067035690.1, WP_103564314.1, WP_129849678.1, WP_125627453.1, WP_083947829.1, WP_083303042.1, KOV66859.1, SDH02982.1, PKM30861.1, WP_103939557.1, WP_120781673.1, WP_136529585.1, WP_091310325.1, GAP50618.1, SCF11721.1, WP_130477875.1, KWV30420.1, WP_143713288.1, WP_107417268.1, WP_106966793.1, WP_092287378.1, WP_080048780.1, WP_122982115.1, PWK87198.1, KYG52038.1, OUE26840.1, WP_052685689.1, SBV25448.1, MAM88718.1, RZI82703.1, WP_107115530.1, KJK32958.1, WP_146103553.1, WP_132628273.1, ALD14029.1, RZL00883.1, WP_148029222.1, WP_105645204.1, WP_108710096.1, An amino acid sequence selected from WP_020639922.1 and WP_132200424.1;
[0107] (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of (i);
[0108] (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i);
[0109] (iv) a polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions, medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (a) a mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) a full-length complement of (a) or (b); and
[0110] (v) a functional fragment having PET decomposition activity of any one of the polypeptides (i) to (iv) above;
[0111] Having an amino acid sequence selected from among
[0112] Based on the reference sequence, sequence number 1,
[0113] (1) The residue corresponding to position 62 is F, W or Y;
[0114] (2) The residue corresponding to position 70 is P;
[0115] (3) The residue corresponding to position 81 is I, L, M or V;
[0116] (4) The residue corresponding to position 85 is P;
[0117] (5) The residue corresponding to position 86 is G;
[0118] (6) The residue corresponding to position 94 is I, L, M or V;
[0119] (7) The residue corresponding to position 95 is A or S;
[0120] (8) The residue corresponding to position 96 is A or S;
[0121] (9) The residue corresponding to position 98 is G;
[0122] (10) The residue corresponding to position 99 is F, W or Y;
[0123] (11) The residue corresponding to position 100 is V, L, I or M;
[0124] (12) The residue corresponding to position 101 is V, L, I or M;
[0125] (13) The residue corresponding to position 113 is D, N or E;
[0126] (14) The residue corresponding to position 118 is R, Q or K;
[0127] (15) The residue corresponding to position 135 is Q, R, E or K;
[0128] (16) The residue corresponding to position 157 is D, N or E;
[0129] (17) The residue corresponding to position 165 is G;
[0130] (18) The residue corresponding to position 167 is S, A, N or T;
[0131] (19) The residue corresponding to position 169 is G;
[0132] (20) The residue corresponding to position 170 is G;
[0133] (21) The residue corresponding to position 262 is D, N or E.
[0134] (22) The residue corresponding to position 304 is H, N or Y;
[0135] (23) The residue corresponding to position 322 is W, F or Y; and
[0136] (24) The residue corresponding to position 330 is D, N or E;
[0137] It may contain an amino acid sequence.
[0138] As one of the specific examples described above, the polypeptide having the PET decomposition activity is
[0139] (i) SDZ16714.1, SHM40309.1, WP_117215036.1, WP_084434874.1, WP_116180173.1, WP_109362551.1, WP_091553551.1, WP_132413760.1, OGB27210.1, WP_101366623.1, WP_124822775.1, WP_110567505.1, WP_054022242.1, WP_130464304.1, WP_073887759.1, WP_088988822.1, WP_082377728.1, WP_132386942.1, CCH19814.1, WP_039906502.1, WP_132337032.1 and PIG53436.1, WP_082403176.1, WP_137976057.1, WP_085749752.1, WP_125191182.1, WP_141984372.1, WP_155388305.1, WP_013736455.1, WP_143590710.1, WP_139584963.1, WP_078759821.1, AEV21261.1, WP_083950838.1, An amino acid sequence selected from among KWV31814.1, ADV92525.1 and OKK16161.1; (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of (i); (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i); (iv) a polypeptide encoded by a polynucleotide that hybridizes to the mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) a full-length complement of (a) or (b) under low stringency conditions, medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions; and (v) a functional fragment having PET degrading activity of any one of the polypeptides of (i) to (iv).
[0140] Based on the reference sequence, sequence number 1,
[0141] (1) The residue corresponding to position 62 is F, W or Y;
[0142] (2) The residue corresponding to position 70 is P;
[0143] (3) The residue corresponding to position 81 is I, L, M or V;
[0144] (4) The residue corresponding to position 85 is P;
[0145] (5) The residue corresponding to position 86 is G;
[0146] (6) The residue corresponding to position 94 is I, L, M or V;
[0147] (7) The residue corresponding to position 95 is A or S;
[0148] (8) The residue corresponding to position 96 is A or S;
[0149] (9) The residue corresponding to position 98 is G;
[0150] (10) The residue corresponding to position 99 is F, W or Y;
[0151] (11) The residue corresponding to position 100 is V, L, I or M;
[0152] (12) The residue corresponding to position 101 is V, L, I or M;
[0153] (13) The residue corresponding to position 113 is D, N or E;
[0154] (14) The residue corresponding to position 118 is R, Q or K;
[0155] (15) The residue corresponding to position 135 is Q, R, E or K;
[0156] (16) The residue corresponding to position 157 is D, N or E;
[0157] (17) The residue corresponding to position 165 is G;
[0158] (18) The residue corresponding to position 167 is S, A, N or T;
[0159] (19) The residue corresponding to position 169 is G;
[0160] (20) The residue corresponding to position 170 is G;
[0161] (21) The residue corresponding to position 262 is D, N or E.
[0162] (22) The residue corresponding to position 304 is H, N or Y;
[0163] (23) The residue corresponding to position 322 is W, F or Y; and
[0164] (24) The residue corresponding to position 330 is D, N or E;
[0165] It may contain an amino acid sequence.
[0166]
[0167] As one of the specific examples described above, the polypeptide having the PET decomposition activity is
[0168] (i) SDZ16714.1, SHM40309.1, WP_117215036.1, WP_084434874.1, WP_116180173.1, WP_109362551.1, WP_091553551.1, WP_132413760.1, OGB27210.1, WP_101366623.1, WP_124822775.1, WP_110567505.1, WP_054022242.1, WP_130464304.1, WP_073887759.1, WP_088988822.1, WP_082377728.1, An amino acid sequence selected from WP_132386942.1, CCH19814.1, WP_039906502.1, WP_132337032.1 and PIG53436.1; (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of (i); (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i); (iv) a polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions, moderate stringency conditions, moderately high stringency conditions, high stringency conditions, or very high stringency conditions with the mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) the full-length complement of (a) or (b); and (v) an amino acid sequence selected from among functional fragments having PET decomposition activity of any one of the polypeptides (i) to (iv).
[0169] Based on the reference sequence, sequence number 1,
[0170] (1) The residue corresponding to position 62 is F, W or Y;
[0171] (2) The residue corresponding to position 70 is P;
[0172] (3) The residue corresponding to position 81 is I, L, M or V;
[0173] (4) The residue corresponding to position 85 is P;
[0174] (5) The residue corresponding to position 86 is G;
[0175] (6) The residue corresponding to position 94 is I, L, M or V;
[0176] (7) The residue corresponding to position 95 is A or S;
[0177] (8) The residue corresponding to position 96 is A or S;
[0178] (9) The residue corresponding to position 98 is G;
[0179] (10) The residue corresponding to position 99 is F, W or Y;
[0180] (11) The residue corresponding to position 100 is V, L, I or M;
[0181] (12) The residue corresponding to position 101 is V, L, I or M;
[0182] (13) The residue corresponding to position 113 is D, N or E;
[0183] (14) The residue corresponding to position 118 is R, Q or K;
[0184] (15) The residue corresponding to position 135 is Q, R, E or K;
[0185] (16) The residue corresponding to position 157 is D, N or E;
[0186] (17) The residue corresponding to position 165 is G;
[0187] (18) The residue corresponding to position 167 is S, A, N or T;
[0188] (19) The residue corresponding to position 169 is G;
[0189] (20) The residue corresponding to position 170 is G;
[0190] (21) The residue corresponding to position 262 is D, N or E.
[0191] (22) The residue corresponding to position 304 is H, N or Y;
[0192] (23) The residue corresponding to position 322 is W, F or Y; and
[0193] (24) The residue corresponding to position 330 is D, N or E;
[0194] It may contain an amino acid sequence.
[0195]
[0196] As any one of the specific examples described above, the polypeptide having PET decomposition activity has at least 80% sequence identity or homology with WP_039906502.1.
[0197]
[0198] Another aspect of the present application is a composition comprising a polypeptide having PET decomposition activity.
[0199] As one of the above specific examples, the composition may be a composition for decomposing PET.
[0200] Another aspect of the present application is a polynucleotide encoding a polypeptide having the PET decomposition activity.
[0201] Another aspect of the present application is a nucleic acid structure comprising the polynucleotide.
[0202] Another aspect of the present application is a vector comprising the polynucleotide or the nucleic acid construct.
[0203] Another aspect of the present application is a host cell comprising the polypeptide having the PET decomposition activity, the polynucleotide, the nucleic acid construct, and / or the vector.
[0204]
[0205] Another aspect of the present application is a method for producing a polypeptide having PET decomposition activity, comprising the steps of culturing the host cell; and recovering the polypeptide having PET decomposition activity expressed in the culturing step.
[0206]
[0207] Another aspect of the present application is a method for degrading a polyester, comprising contacting a polyester with a polypeptide having PET degrading activity, a host cell expressing the polypeptide having PET degrading activity, and / or a composition comprising the polypeptide having PET degrading activity.
[0208] As one of the above specific examples, the polyester may be PET.
[0209] Another aspect of the present application is a method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA) and / or ethylene glycol (EG), comprising contacting a polyester with a polypeptide having PET degrading activity, a host cell expressing the polypeptide having PET degrading activity, and / or a composition comprising the polypeptide having PET degrading activity.
[0210] As one of the above specific examples, the polyester may be PET.
[0211] As one of the above specific examples, the method may further include a step of recovering MHET, TPA, and / or EG produced by the method.
[0212] Another aspect of the present application is a method for synthesizing polyester using MHET, TPA, and / or EG prepared by the above method.
[0213] As one of the above specific examples, the polyester may be PET.
[0214]
[0215] Another aspect of the present application is the use of the polypeptide, a host cell expressing the polypeptide, and / or a composition comprising the polypeptide for PET degradation.
[0216] Another aspect of the present application is the use of a polypeptide having PET decomposition activity and / or a composition comprising said polypeptide for reaction with polyester in the production of mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG).
[0217]
[0218] The specific details for implementing the invention are as follows. Furthermore, each description and embodiment disclosed in this application can be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0219] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.
[0220] Additionally, numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety, thereby providing a clearer understanding of the technical field to which this application pertains and the content of this application.
[0221]
[0222] As used in the specification and appended claims of this application, the singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Unless the context clearly dictates otherwise, the singular terms include the plural and the plural terms include the singular. In the specification and appended claims of this application, unless the context clearly dictates otherwise, the use of "or" is intended to include "and / or."
[0223]
[0224] In this application, the term "about" may be used before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is or is nearly that number. Whether a number is or is nearly the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. In another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. However, this is not a limitation.
[0225]
[0226] In this application, the terms "first, second, third, …," "i), ii), iii)…" or "(a), (b), (c), (d)…" are used to distinguish similar configurations, and these terms do not imply that the steps are performed consecutively or in order. For example, when the terms are used in relation to steps of a method, use, or analysis, these steps may be performed simultaneously, or may be performed at intervals of seconds, minutes, hours, days, or months.
[0227]
[0228] In this application, the term "consisting essentially of" means that a non-specific component may be present if the characteristics of the subject matter claimed in this application are not substantially affected by the presence of the non-specific component.
[0229] In this application, the term "consisting of" means that the proportion of a specific component(s) totals 100%. The components or features listed below the term "consisting of" may be essential or mandatory. In some embodiments, other than the components or features listed below "consisting of," other optional or nonessential components may be excluded.
[0230] In this application, the term "comprising" means the presence of a feature, step, or component described below, and does not exclude the presence or addition of one or more features, steps, or components. The components or features described below "comprising" in this application may be essential or mandatory, but in some embodiments, other optional or non-essential components or features may be further included.
[0231] In this application, the term “comprising” may, in some embodiments, be modified to refer to “consisting essentially of” or “consisting of.”
[0232] In this application, with respect to an amino acid sequence, even if a polypeptide "comprising" an amino acid sequence described in a specific sequence, a polypeptide "consisting of" an amino acid sequence described in a specific sequence, or a polypeptide or protein "having" an amino acid sequence described in a specific sequence is described, it is obvious that a protein having an amino acid sequence in which a portion of the sequence is deleted, modified, substituted, conservatively substituted, or added may also be used in this application, as long as it has the same or corresponding activity as a polypeptide consisting of the amino acid sequence of the corresponding sequence. For example, it may have a case in which it has a sequence addition that does not alter the function of the protein at the N-terminus and / or C-terminus of the amino acid sequence, a mutation that may occur naturally, a silent mutation thereof, or a conservative substitution, but is not limited thereto. Meanwhile, the sequence information of the amino acid sequence described by name in this application can be found in a known database, for example, NCBI (https: / www.ncbi.nlm.nih.gov / ), Uniprot, etc.
[0233]
[0234] In this application, the term "protein" or "polypeptide" refers to a polymer or oligomer of consecutive amino acid residues. In this application, "polypeptide," "protein," and "peptide" may be used interchangeably with "amino acid sequence."
[0235] In some cases, an amino acid sequence that exhibits activity may be referred to as an "enzyme." In this application, amino acid sequences are described in N-terminal → C-terminal orientation, unless otherwise indicated.
[0236]
[0237] In relation to a cell, nucleic acid, polypeptide, or vector, the term "recombinant" in this application means that the cell, nucleic acid, polypeptide, or vector has been modified by the introduction of a heterologous nucleic acid or polypeptide or by alteration of a native nucleic acid or polypeptide, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell may express a gene not found in the native (non-recombinant) form of the cell, or may express a native gene that is expressed or not expressed at all, or otherwise abnormally expressed.
[0238]
[0239] As used herein, the term "isolated" refers to a substance that exists in an environment where it does not occur naturally, or in a form that does not occur naturally. This includes the substance (sequence, enzyme, or nucleic acid) being at least substantially free from at least one other component with which it is naturally associated and found in nature, such as a sequence, enzyme, or nucleic acid.
[0240] For example, the isolated sequences, enzymes or nucleic acids provided in the present application may be provided in a form substantially free of one or more contaminants.
[0241] Examples of isolated substances may include, but are not limited to, i) any non-naturally occurring substance, ii) any substance from which one, more, or all naturally occurring components associated with it in nature have been removed (e.g., an enzyme, variant, nucleic acid, protein, peptide, or cofactor), iii) any substance found in nature that has been artificially modified, or iv) a substance that has been modified to alter the amount of that substance relative to other naturally associated components (e.g., increasing the number of copies of a gene encoding the substance; modifying a promoter naturally associated with a gene encoding the substance to a more active promoter, etc.).
[0242]
[0243] In the present application, with respect to an amino acid or nucleic acid sequence, the term "fragment" means a portion of a parent sequence. For example, it may be a polypeptide in which one or more amino acids from the parent sequence are removed from the C or N terminus.
[0244] In the present application, a "fragment" of an enzyme may refer to a "functional fragment." A "functional fragment," also referred to as an "active fragment," refers to a polypeptide that is part of a parent enzyme and possesses the enzymatic activity of the parent enzyme. For example, a functional fragment of an enzyme may include the catalytic site of the enzyme.
[0245] The enzyme fragment may comprise a portion of the full length of the parent enzyme, for example, but not limited to, at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or less than 100% of the amino acids of the full length of the parent enzyme.
[0246]
[0247] Throughout this application, the conventional one-letter and three-letter codes for naturally occurring amino acids are used. Furthermore, amino acids referred to by abbreviations in this application are described according to the IUPAC-IUB nomenclature.
[0248]
[0249] Alanine Ala, A Arginine Arg, R
[0250] Asparagine Asn, N Aspartic acid Asp, D
[0251] Cysteine Cys, C Glutamic acid Glu, E
[0252] Glutamine Gln, Q Glycine Gly, G
[0253] Histidine His, H Isoleucine Ile, I
[0254] Leucine Leu, L Lysine Lys, K
[0255] Methionine Met, M Phenylalanine Phe, F
[0256] Proline Pro, P Serine Ser, S
[0257] Threonine Thr, T Tryptophan Trp, W
[0258] Tyrosine Tyr, Y Valine Val, V
[0259]
[0260] Meanwhile, any amino acid can be written as Xaa, X.
[0261] Additionally, the generally accepted three-letter codes for other amino acids, such as Aib (2-Aminoisobutyric acid), Sar (N-methylglycine), and α-methyl-glutamic acid, may be used, as well as for naturally occurring amino acids.
[0262] Amino acids can generally be classified based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Accordingly, amino acid substitutions can generally occur based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues.
[0263] For example, among the amino acids having electrically charged side chains, positively charged (basic) amino acids include arginine, lysine, and histidine, and negatively charged (acidic) amino acids include glutamic acid and aspartic acid; among the amino acids having uncharged side chains, nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline, and polar or hydrophilic amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine, and among the nonpolar amino acids, aromatic amino acids include phenylalanine, tryptophan, and tyrosine.
[0264]
[0265] As used herein, the term "gene" refers to a polynucleotide encoding a polypeptide and a polynucleotide comprising regions preceding and following the coding region. In some embodiments, a gene may have a sequence (intron) inserted between each coding region (exon).
[0266]
[0267] As used herein, the terms "homology" or "identity" refer to the degree of relationship between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms "homology" and "identity" are often used interchangeably.
[0268] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences are generally capable of hybridizing under moderate or high stringency conditions, typically along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its entire length. It should be appreciated that hybridization also encompasses polynucleotides containing common codons or codons that are considered codon degenerate.
[0269] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ET al.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using, but is not limited to, BLAST from the National Center for Biotechnology Information Database, or ClustalW.
[0270] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). The default parameters for the GAP program are (1) a unitary matrix (containing values of 1 for identity and 0 for non-identity) and (2) a matrix of 1s for identity and 0s for non-identity, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979), Gribskov et al. (1986) Nucl. Acids Res. 48:443. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0271] Additionally, whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, but are not limited thereto).
[0272]
[0273] In this application, the term "mature polypeptide" refers to a polypeptide in a form that lacks a signal sequence or a propeptide sequence. A mature protein / polypeptide / peptide may be a functional form of a protein / polypeptide / peptide. A mature polypeptide may be a final form that has undergone post-translational or post-translational modifications. Examples of post-translational modifications include, but are not limited to, N- or C-terminal modifications, glycosylation, phosphorylation, and leader sequence removal.
[0274]
[0275] The term "nucleic acid construct" in this application means a single or double-stranded nucleic acid molecule that contains one or more regulatory sequences and is artificially synthesized, engineered to contain a specific sequence in a manner that does not exist in nature, or isolated from nature.
[0276]
[0277] As used herein, the term “expression” includes, but is not limited to, any step involved in the production of a polypeptide, such as transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0278] As used herein, the term "expression vector" means a linear or circular nucleic acid molecule comprising a coding sequence and regulatory sequences operably linked thereto for expression thereof.
[0279]
[0280] As used herein, the term "operably linked" refers to a configuration in which a regulatory sequence is positioned appropriately to direct the expression of a coding sequence. Therefore, "operably linked" includes a regulatory region of a functional domain with known or desired activity, such as a promoter, terminator, signal sequence, or enhancer region, attached or linked to a target (gene or polypeptide) so as to regulate the expression, secretion, or function of the target in accordance with the known or desired activity.
[0281]
[0282] In this application, the term "reference sequence" refers to a sequence used to determine the position of an amino acid within an arbitrary amino acid sequence. By aligning an arbitrary amino acid sequence with a reference sequence, the position of an amino acid corresponding to a specific position of the reference sequence within the arbitrary amino acid sequence can be determined. In other words, it can be used as a reference point when determining the position of an amino acid in a group of amino acid sequences that have various sequence lengths and different amino acid arrangements, but identically contain specific motifs. This is distinct from the parent sequence or backbone that is the target for introducing a modification.
[0283] In this application, the term "alignment" of sequences refers to the expression of the degree to which two or more sequences are functionally or evolutionarily related, and which parts of the sequences have such a relationship. Sequence alignment is created through calculations based on certain criteria, and because the calculation process is complex and requires a large amount of calculations, it is used as a computer program. Various programs can be used to perform sequence alignment, and representative programs such as ClustalV, ClustalW, and ClustalX can be utilized for aligning multiple sequences.
[0284] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a protein or polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the protein or polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a particular sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.
[0285] In the present application, the COG4188 consensus sequence of SEQ ID NO. 1 can be used as a reference sequence to determine the position of an amino acid in any amino acid sequence.
[0286] That is, SEQ ID NO: 1 disclosed in the present application can be used to determine the corresponding amino acid residue in a polypeptide having any PET decomposition activity. This means that the amino acid sequence of SEQ ID NO: 1 is a reference sequence, not a parent sequence. Therefore, the description in the present application such as "based on SEQ ID NO: 1, the amino acid corresponding to the Nth position is G" is interpreted to mean that when the amino acid sequence of any polypeptide is aligned with the amino acid sequence of SEQ ID NO: 1, the amino acid corresponding to the Nth position of SEQ ID NO: 1 is G in the amino acid sequence of any polypeptide. In addition, it is not limited to the meaning that the amino acid sequence of any polypeptide has the same residue as SEQ ID NO: 1 at a position other than the Nth amino acid, and is not interpreted to mean that any polypeptide includes the amino acid sequence of SEQ ID NO: 1.
[0287] For example, the amino acid sequence of any polypeptide can be aligned with SEQ ID NO: 1, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 1. For example, a sequence alignment algorithm such as that described in the present application can identify the position of an amino acid, or a position where a modification such as a substitution, insertion, or deletion occurs, or a residue that is identical to the reference sequence, by comparing it with a query sequence (also referred to as a “reference sequence”). If an amino acid at a position corresponding to a specific position in SEQ ID NO: 1 in any amino acid sequence is different from SEQ ID NO: 1, the amino acid can be expressed as being modified (e.g., substituted), and if it is the same, the amino acid can be expressed as being maintained or preserved.
[0288] In the present application, a position corresponding to a specific amino acid of SEQ ID NO. 1 within any sequence is defined by displaying the results of multiple alignment using the ClustalW2 program (Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG.(2007). Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947-2948, see http: / www.clustal.org / clustal2) of a gene encoding the following 152 amino acid sequences based on SEQ ID NO. 1, wherein the parameters are default values:
[0289] WP_109362551.1, SHM40309.1, SDZ16714.1, WP_084434874.1, WP_101366623.1, WP_117215036.1, WP_132413760.1, WP_110567505.1, WP_143590710.1, WP_091553551.1, WP_124822775.1, WP_116180173.1, OGB27210.1, WP_088988822.1, WP_125191182.1, WP_085749752.1, WP_130464304.1, WP_054022242.1, WP_082377728.1, WP_132386942.1, WP_082403176.1, WP_013736455.1, WP_073887759.1, CCH19814.1, WP_141984372.1, WP_155388305.1, WP_039906502.1, WP_137976057.1, WP_132337032.1, WP_093411427.1, WP_075737041.1, WP_139584963.1, WP_088276085.1, PIG53436.1, WP_045318561.1, WP_078759821.1, AEV21261.1, WP_047194864.1, WP_083950838.1, KWV31814.1, ADV92525.1, EOD65379.1, WP_013229249.1, WP_131056699.1, WP_072476921.1, WP_065917710.1, WP_130401777.1, WP_081971423.1, WP_086849962.1, WP_109639600.1, WP_150303381.1, WP_076469402.1, WP_086784246.1, WP_125313231.1, WP_120675340.1, WP_027346283.1, WP_155541557.1, WP_075975245.1, WP_144126986.1, WP_078844206.1, WP_091283529.1, WP_103503499.1, WP_130969140.1, WP_112669767.1, KNX38636.1, GBD22443.1, WP_083302694.1, WP_091084084.1, WP_093954453.1, WP_116813002.1, WP_089021493.1, PWK39581.1, WP_011291330.1, WP_123685830.1, WP_123748612.1, WP_084400763.1, WP_132183354.1, ADV92527.1, WP_014689902.1, WP_093935592.1, RZS34008.1, WP_138709315.1, WP_141569747.1, 1JFR_A, WP_124770494.1, 4WFI_A, WP_143737449.1, WP_080041749.1, CBY05529.1, WP_111700265.1, OKK16161.1, WP_143320421.1, WP_084578793.1, WP_104613137.1, WP_104115406.1, SPF04022.1, WP_119701604.1, WP_120326365.1, PWW60275.1, WP_086668955.1, WP_092528534.1, WP_063729606.1, 3VIS_A, WP_138698985.1, WP_145923095.1, WP_068752972.1, MBA55398.1, WP_123888242.1, WP_083724990.1, WP_044499735.1, WP_051808300.1, WP_067035690.1, WP_103564314.1, WP_129849678.1, WP_125627453.1, WP_083947829.1, WP_083303042.1, KOV66859.1, SDH02982.1, PKM30861.1, WP_103939557.1, WP_120781673.1, WP_136529585.1, WP_091310325.1, GAP50618.1, SCF11721.1, WP_130477875.1, KWV30420.1, WP_143713288.1, WP_107417268.1, WP_106966793.1, WP_092287378.1, WP_080048780.1, WP_122982115.1, PWK87198.1, KYG52038.1, OUE26840.1, WP_052685689.1, SBV25448.1, MAM88718.1, RZI82703.1, WP_107115530.1, KJK32958.1, WP_146103553.1, WP_132628273.1, ALD14029.1, RZL00883.1, WP_148029222.1, WP_105645204.1, WP_108710096.1, WP_020639922.1 and WP_132200424.1.
[0290]
[0291] A method for identifying a polypeptide having PET decomposition activity of the present application is as follows:
[0292] A step of preparing an amino acid sequence of a polypeptide (predicted polypeptide) expected to have PET decomposition activity;
[0293] A step of aligning the prepared amino acid sequence based on the reference sequence of sequence number 1, and
[0294] A method for identifying a polypeptide having PET decomposition activity, comprising the step of confirming whether the amino acid sequence of the predicted polypeptide from the above alignment results has the following characteristics:
[0295] Based on the reference sequence, sequence number 1,
[0296] (1) The residue corresponding to position 62 is F, W or Y;
[0297] (2) The residue corresponding to position 70 is P;
[0298] (3) The residue corresponding to position 81 is I, L, M or V;
[0299] (4) The residue corresponding to position 85 is P;
[0300] (5) The residue corresponding to position 86 is G;
[0301] (6) The residue corresponding to position 94 is I, L, M or V;
[0302] (7) The residue corresponding to position 95 is A or S;
[0303] (8) The residue corresponding to position 96 is A or S;
[0304] (9) The residue corresponding to position 98 is G;
[0305] (10) The residue corresponding to position 99 is F, W or Y;
[0306] (11) The residue corresponding to position 100 is V, L, I or M;
[0307] (12) The residue corresponding to position 101 is V, L, I or M;
[0308] (13) The residue corresponding to position 113 is D, N or E;
[0309] (14) The residue corresponding to position 118 is R, Q or K;
[0310] (15) The residue corresponding to position 135 is Q, R, E or K;
[0311] (16) The residue corresponding to position 157 is D, N or E;
[0312] (17) The residue corresponding to position 165 is G;
[0313] (18) The residue corresponding to position 167 is S, A, N or T;
[0314] (19) The residue corresponding to position 169 is G;
[0315] (20) The residue corresponding to position 170 is G;
[0316] (21) The residue corresponding to position 262 is D, N or E.
[0317] (22) The residue corresponding to position 304 is H, N or Y;
[0318] (23) The residue corresponding to position 322 is W, F or Y; and
[0319] (24) The residue corresponding to position 330 is D, N or E.
[0320] The terms “alignment” and “corresponding” are as described above.
[0321] In one embodiment, the amino acid sequence of the predicted polypeptide may be one or more, two or more, or multiple. In one embodiment, the method may comprise a step of aligning the amino acid sequences of a plurality of predicted polypeptides.
[0322] In any one of the embodiments described above, the method for identifying a polypeptide having PET degrading activity may comprise the step of confirming whether the predicted polypeptide includes a motif of the following general formulae 1 to 5:
[0323] (General formula 1) X1-X2-X3-X4-X5-X6-X7-X8-P:
[0324] where X1 is F, W, or Y; and
[0325] X2 to X8 are any amino acid or absent;
[0326] (General formula 2)X1-X2-X3-X4-PG:
[0327] where X1 is I, L, M or V; and
[0328] X2 to X4 are any amino acid or absent;
[0329] (General formula 3) X1-X2-X3-X4-G-X5-X6-X7:
[0330] X1 is I, L, M or V;
[0331] X2 is A or S;
[0332] X3 is A or S;
[0333] X4 is any amino acid or absent;
[0334] X5 is F, W or Y;
[0335] X6 is V, L, I or M; and
[0336] X7 is V, L, I or M;
[0337] (General formula 4)
[0338] X1-X2-X3-X4-X5-X6-X7-X8-G-X9-X10-X11-GG
[0339] Here, X1 is D, N or E;
[0340] X2 to X8, X9 and X11 are any amino acid or absent; and
[0341] X10 is S, A, N or T;
[0342] (General Formula 5)
[0343] X1-X2-X3-X4-X5-X6-X7-X8-X9
[0344] Here, X1 is W, F or Y;
[0345] X2 to X8 are any amino acid or absent; and
[0346] X9 is D, N or E.
[0347]
[0348] The polypeptide having PET decomposition activity provided in the present application is based on the reference sequence, SEQ ID NO. 1.
[0349] (1) The residue corresponding to position 62 is F, W or Y;
[0350] (2) The residue corresponding to position 70 is P;
[0351] (3) The residue corresponding to position 81 is I, L, M or V;
[0352] (4) The residue corresponding to position 85 is P;
[0353] (5) The residue corresponding to position 86 is G;
[0354] (6) The residue corresponding to position 94 is I, L, M or V;
[0355] (7) The residue corresponding to position 95 is A or S;
[0356] (8) The residue corresponding to position 96 is A or S;
[0357] (9) The residue corresponding to position 98 is G;
[0358] (10) The residue corresponding to position 99 is F, W or Y;
[0359] (11) The residue corresponding to position 100 is V, L, I or M;
[0360] (12) The residue corresponding to position 101 is V, L, I or M;
[0361] (13) The residue corresponding to position 113 is D, N or E;
[0362] (14) The residue corresponding to position 118 is R, Q or K;
[0363] (15) The residue corresponding to position 135 is Q, R, E or K;
[0364] (16) The residue corresponding to position 157 is D, N or E;
[0365] (17) The residue corresponding to position 165 is G;
[0366] (18) The residue corresponding to position 167 is S, A, N or T;
[0367] (19) The residue corresponding to position 169 is G;
[0368] (20) The residue corresponding to position 170 is G;
[0369] (21) The residue corresponding to position 262 is D, N or E.
[0370] (22) The residue corresponding to position 304 is H, N or Y;
[0371] (23) The residue corresponding to position 322 is W, F or Y; and
[0372] (24) The residue corresponding to position 330 is D, N, or E.
[0373] am.
[0374] In one embodiment, the polypeptide of the present application may comprise a motif of the following general formulae 1 to 5:
[0375] (General formula 1) X1-X2-X3-X4-X5-X6-X7-X8-P:
[0376] where X1 is F, W, or Y; and
[0377] X2 to X8 are any amino acid or absent;
[0378] (General formula 2) X1-X2-X3-X4-PG:
[0379] where X1 is I, L, M or V; and
[0380] X2 to X4 are any amino acid or absent;
[0381] (General formula 3) X1-X2-X3-X4-G-X5-X6-X7:
[0382] X1 is I, L, M or V;
[0383] X2 is A or S;
[0384] X3 is A or S;
[0385] X4 is any amino acid or absent;
[0386] X5 is F, W or Y;
[0387] X6 is V, L, I or M; and
[0388] X7 is V, L, I or M;
[0389] (General formula 4)
[0390] X1-X2-X3-X4-X5-X6-X7-X8-G-X9-X10-X11-GG
[0391] Here, X1 is D, N or E;
[0392] X2 to X8, X9 and X11 are any amino acid or absent; and
[0393] X10 is S, A, N or T;
[0394] (General Formula 5)
[0395] X1-X2-X3-X4-X5-X6-X7-X8-X9
[0396] Here, X1 is W, F or Y;
[0397] X2 to X8 are any amino acid or absent; and
[0398] X9 is D, N or E.
[0399]
[0400] In any one of the above-described embodiments, the polypeptide having PET decomposition activity provided in the present application is
[0401] (i) WP_109362551.1, SHM40309.1, SDZ16714.1, WP_084434874.1, WP_101366623.1, WP_117215036.1, WP_132413760.1, WP_110567505.1, WP_143590710.1, WP_091553551.1, WP_124822775.1, WP_116180173.1, OGB27210.1, WP_088988822.1, WP_125191182.1, WP_085749752.1, WP_130464304.1, WP_054022242.1, WP_082377728.1, WP_132386942.1, WP_082403176.1, WP_013736455.1, WP_073887759.1, CCH19814.1, WP_141984372.1, WP_155388305.1, WP_039906502.1, WP_137976057.1, WP_132337032.1, WP_093411427.1, WP_075737041.1, WP_139584963.1, WP_088276085.1, PIG53436.1, WP_045318561.1, WP_078759821.1, AEV21261.1, WP_047194864.1, WP_083950838.1, KWV31814.1, ADV92525.1, EOD65379.1, WP_013229249.1, WP_131056699.1, WP_072476921.1, WP_065917710.1, WP_130401777.1, WP_081971423.1, WP_086849962.1, WP_109639600.1, WP_150303381.1, WP_076469402.1, WP_086784246.1, WP_125313231.1, WP_120675340.1, WP_027346283.1, WP_155541557.1, WP_075975245.1, WP_144126986.1, WP_078844206.1, WP_091283529.1, WP_103503499.1, WP_130969140.1, WP_112669767.1, KNX38636.1, GBD22443.1, WP_083302694.1, WP_091084084.1, WP_093954453.1, WP_116813002.1, WP_089021493.1, PWK39581.1, WP_011291330.1, WP_123685830.1, WP_123748612.1, WP_084400763.1, WP_132183354.1, ADV92527.1, WP_014689902.1, WP_093935592.1, RZS34008.1, WP_138709315.1, WP_141569747.1, 1JFR_A, WP_124770494.1, 4WFI_A, WP_143737449.1, WP_080041749.1, CBY05529.1, WP_111700265.1, OKK16161.1, WP_143320421.1, WP_084578793.1, WP_104613137.1, WP_104115406.1, SPF04022.1, WP_119701604.1, WP_120326365.1, PWW60275.1, WP_086668955.1, WP_092528534.1, WP_063729606.1, 3VIS_A, WP_138698985.1, WP_145923095.1, WP_068752972.1, MBA55398.1, WP_123888242.1, WP_083724990.1, WP_044499735.1, WP_051808300.1, WP_067035690.1, WP_103564314.1, WP_129849678.1, WP_125627453.1, WP_083947829.1, WP_083303042.1, KOV66859.1, SDH02982.1, PKM30861.1, WP_103939557.1, WP_120781673.1, WP_136529585.1, WP_091310325.1, GAP50618.1, SCF11721.1, WP_130477875.1, KWV30420.1, WP_143713288.1, WP_107417268.1, WP_106966793.1, WP_092287378.1, WP_080048780.1, WP_122982115.1, PWK87198.1, KYG52038.1, OUE26840.1, WP_052685689.1, SBV25448.1, MAM88718.1, RZI82703.1, WP_107115530.1, KJK32958.1, WP_146103553.1, WP_132628273.1, ALD14029.1, RZL00883.1, WP_148029222.1, WP_105645204.1, WP_108710096.1, An amino acid sequence selected from WP_020639922.1 and WP_132200424.1;
[0402] (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of (i);
[0403] (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i);
[0404] (iv) a polypeptide encoded by a mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) a polynucleotide that hybridizes with the full-length complement of (a) or (b) under low stringency conditions, medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions; and
[0405] (v) a functional fragment having PET decomposition activity of any one of the polypeptides (i) to (iv) above;
[0406] having, comprising, or consisting of an amino acid sequence selected from the group consisting of:
[0407] Based on the reference sequence, sequence number 1, (1) the residue corresponding to position 62 is F, W or Y;
[0408] (2) The residue corresponding to position 70 is P;
[0409] (3) The residue corresponding to position 81 is I, L, M or V;
[0410] (4) The residue corresponding to position 85 is P;
[0411] (5) The residue corresponding to position 86 is G;
[0412] (6) The residue corresponding to position 94 is I, L, M or V;
[0413] (7) The residue corresponding to position 95 is A or S;
[0414] (8) The residue corresponding to position 96 is A or S;
[0415] (9) The residue corresponding to position 98 is G;
[0416] (10) The residue corresponding to position 99 is F, W or Y;
[0417] (11) The residue corresponding to position 100 is V, L, I or M;
[0418] (12) The residue corresponding to position 101 is V, L, I or M;
[0419] (13) The residue corresponding to position 113 is D, N or E;
[0420] (14) The residue corresponding to position 118 is R, Q or K;
[0421] (15) The residue corresponding to position 135 is Q, R, E or K;
[0422] (16) The residue corresponding to position 157 is D, N or E;
[0423] (17) The residue corresponding to position 165 is G;
[0424] (18) The residue corresponding to position 167 is S, A, N or T;
[0425] (19) The residue corresponding to position 169 is G;
[0426] (20) The residue corresponding to position 170 is G;
[0427] (21) The residue corresponding to position 262 is D, N or E.
[0428] (22) The residue corresponding to position 304 is H, N or Y;
[0429] (23) The residue corresponding to position 322 is W, F or Y; and
[0430] (24) It may include an amino acid sequence in which the residue corresponding to position 330 is D, N or E,
[0431] If it has the same or corresponding activity as the polypeptide of the above (i), it can be included without limitation in the scope of the polypeptide having PET decomposition activity of the present application.
[0432]
[0433] In any one of the embodiments described above, the polypeptide having PET decomposition activity is
[0434] (i) SDZ16714.1, SHM40309.1, WP_117215036.1, WP_084434874.1, WP_116180173.1, WP_109362551.1, WP_091553551.1, WP_132413760.1, OGB27210.1, WP_101366623.1, WP_124822775.1, WP_110567505.1, WP_054022242.1, WP_130464304.1, WP_073887759.1, WP_088988822.1, WP_082377728.1, WP_132386942.1, CCH19814.1, WP_039906502.1, WP_132337032.1 및 PIG53436.1, WP_082403176.1, WP_137976057.1, WP_085749752.1, WP_125191182.1, WP_141984372.1, WP_155388305.1, WP_013736455.1, WP_143590710.1, WP_139584963.1, WP_078759821.1, AEV21261.1, WP_083950838.1, KWV31814.1, ADV92525.1 및 OKK16161.1. An amino acid sequence selected from the group consisting of: (i) an amino acid sequence having at least 70% identity with the amino acid sequence of (i); (ii) an amino acid sequence having at least 70% sequence identity with the sequence encoding a mature polypeptide of the amino acid sequence of (i); (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i); (iv) a polypeptide encoded by a polynucleotide that hybridizes to the mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) a full-length complement of (a) or (b) under low stringency conditions, medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions; and (v) a functional fragment having PET degrading activity of any one of the polypeptides of (i) to (iv).
[0435] Based on the reference sequence, sequence number 1
[0436] (1) The residue corresponding to position 62 is F, W or Y;
[0437] (2) The residue corresponding to position 70 is P;
[0438] (3) The residue corresponding to position 81 is I, L, M or V;
[0439] (4) The residue corresponding to position 85 is P;
[0440] (5) The residue corresponding to position 86 is G;
[0441] (6) The residue corresponding to position 94 is I, L, M or V;
[0442] (7) The residue corresponding to position 95 is A or S;
[0443] (8) The residue corresponding to position 96 is A or S;
[0444] (9) The residue corresponding to position 98 is G;
[0445] (10) The residue corresponding to position 99 is F, W or Y;
[0446] (11) The residue corresponding to position 100 is V, L, I or M;
[0447] (12) The residue corresponding to position 101 is V, L, I or M;
[0448] (13) The residue corresponding to position 113 is D, N or E;
[0449] (14) The residue corresponding to position 118 is R, Q or K;
[0450] (15) The residue corresponding to position 135 is Q, R, E or K;
[0451] (16) The residue corresponding to position 157 is D, N or E;
[0452] (17) The residue corresponding to position 165 is G;
[0453] (18) The residue corresponding to position 167 is S, A, N or T;
[0454] (19) The residue corresponding to position 169 is G;
[0455] (20) The residue corresponding to position 170 is G;
[0456] (21) The residue corresponding to position 262 is D, N or E.
[0457] (22) The residue corresponding to position 304 is H, N or Y;
[0458] (23) The residue corresponding to position 322 is W, F or Y; and
[0459] (24) The residue corresponding to position 330 may be D, N or E.
[0460]
[0461] In any one of the embodiments described above, the polypeptide having PET decomposition activity is
[0462] (i) SDZ16714.1, SHM40309.1, WP_117215036.1, WP_084434874.1, WP_116180173.1, WP_109362551.1, WP_091553551.1, WP_132413760.1, OGB27210.1, WP_101366623.1, WP_124822775.1, WP_110567505.1, WP_054022242.1, WP_130464304.1, WP_073887759.1, WP_088988822.1, WP_082377728.1, An amino acid sequence selected from WP_132386942.1, CCH19814.1, WP_039906502.1, WP_132337032.1 and PIG53436.1; (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of (i); (iii) a polypeptide encoded by a polynucleotide having at least 70% sequence identity with a sequence encoding a mature polypeptide of the amino acid sequence of (i); (iv) a polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions, moderate stringency conditions, moderately high stringency conditions, high stringency conditions, or very high stringency conditions with the mature polypeptide coding sequence of the amino acid sequence of (i), (b) a cDNA thereof, or (c) the full-length complement of (a) or (b); and (v) has, comprises, or consists of an amino acid sequence selected from the functional fragments having PET decomposition activity of any one of the polypeptides (i) to (iv) above,
[0463] Based on the reference sequence, sequence number 1
[0464] (1) The residue corresponding to position 62 is F, W or Y;
[0465] (2) The residue corresponding to position 70 is P;
[0466] (3) The residue corresponding to position 81 is I, L, M or V;
[0467] (4) The residue corresponding to position 85 is P;
[0468] (5) The residue corresponding to position 86 is G;
[0469] (6) The residue corresponding to position 94 is I, L, M or V;
[0470] (7) The residue corresponding to position 95 is A or S;
[0471] (8) The residue corresponding to position 96 is A or S;
[0472] (9) The residue corresponding to position 98 is G;
[0473] (10) The residue corresponding to position 99 is F, W or Y;
[0474] (11) The residue corresponding to position 100 is V, L, I or M;
[0475] (12) The residue corresponding to position 101 is V, L, I or M;
[0476] (13) The residue corresponding to position 113 is D, N or E;
[0477] (14) The residue corresponding to position 118 is R, Q or K;
[0478] (15) The residue corresponding to position 135 is Q, R, E or K;
[0479] (16) The residue corresponding to position 157 is D, N or E;
[0480] (17) The residue corresponding to position 165 is G;
[0481] (18) The residue corresponding to position 167 is S, A, N or T;
[0482] (19) The residue corresponding to position 169 is G;
[0483] (20) The residue corresponding to position 170 is G;
[0484] (21) The residue corresponding to position 262 is D, N or E.
[0485] (22) The residue corresponding to position 304 is H, N or Y;
[0486] (23) The residue corresponding to position 322 is W, F or Y; and
[0487] (24) The residue corresponding to position 330 may be D, N or E.
[0488]
[0489] In any one of the embodiments described above, the polypeptide having PET decomposition activity may have at least 80% sequence identity or homology with WP_039906502.1. For example, CCH19814.1, WP_110567505.1, WP_112669767.1, WP_124822775.1, WP_089021493.1, WP_139584963.1, WP_130401777.1, PIG53436.1, WP_088988822.1, WP_082377728.1, WP_091553551.1, WP_101366623.1, WP_124770494.1, KWV31814.1, WP_083302694.1, WP_091283529.1, It can be selected from WP_093411427.1, WP_131056699.1, WP_013736455.1, and WP_130464304.1.
[0490]
[0491] In the present application, the terms "polypeptide having PET decomposition activity" and "PET decomposition enzyme (PETase)" refer to an enzyme having a depolymerization activity of polyethylene terephthalate (PET). For example, the PET decomposition enzyme may have an activity not only for depolymerizing PET but also for depolymerizing a low-molecular-weight polymer obtained by depolymerizing PET, such as bis(2-hydroxyethyl) terephthalate (BHET). As another example, the PET decomposition enzyme may have an activity for decomposing polyester bonds.
[0492] In the present application, PET degradation activity can be measured and evaluated using methods known in the art, including the embodiments described in the present application. For example, it can be evaluated by measuring the amount of BHET, MHET, TPA, or EG produced.
[0493] For example, the polypeptide having PET decomposition activity of the present application may be an enzyme derived from a microorganism or a recombinant enzyme.
[0494] Another aspect of the present application provides use of the polypeptide as a PET degrading enzyme.
[0495]
[0496] The "polynucleotide" of the present application may comprise the coding sequence of the aforementioned polypeptide. The polynucleotide may undergo various modifications to the coding region within a range that does not alter the amino acid sequence of the polypeptide, due to codon degeneracy or in consideration of codons preferred by the organism intended to express the polypeptide.
[0497] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known gene sequence, for example, a sequence that hybridizes under stringent conditions with a complementary sequence to all or part of the base sequence, so long as it is a sequence encoding the polypeptide of the present application.
[0498] The above "stringent conditions" refer to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York).
[0499] For example, conditions under which polynucleotides having a high degree of homology or identity hybridize with each other, specifically at least 40%, specifically at least 90%, more specifically at least 95%, at least 96%, at least 97%, at least 98%, and even more specifically at least 99%, and polynucleotides having a lower degree of homology or identity than that hybridize, or conditions under which washing is performed once, specifically twice or three times, at a salt concentration and temperature corresponding to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, can be listed.
[0500] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.
[0501] Specifically, polynucleotides having homology or identity can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C and can be appropriately adjusted by those skilled in the art depending on the purpose.
[0502] The appropriate stringency for hybridizing polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables well known in the art (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8).
[0503] For example, “high stringency” may occur at about 5 to 10°C below the Tm of the probe; “medium stringency” may occur at about 10 to 20°C below the Tm of the probe; and “low stringency” may occur at about 20 to 25°C below the Tm, but is not limited thereto.
[0504] For example, “low stringency conditions” can be prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms / ml of sheared and denatured salmon sperm DNA, and 25% formamide for 12-24 hours, for a probe of at least 100 nucleotides in length, according to standard Southern blotting procedures. The carrier material can be finally washed two to three times for 15 minutes each with 2 X SSC, 0.1 to 0.2% SDS at 50°C.
[0505] For example, “medium stringency conditions” can be prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms / ml of sheared and denatured salmon sperm DNA, and 35% formamide for 12-24 hours, for a probe of at least 100 nucleotides in length, according to standard Southern blotting procedures. The carrier material can be finally washed two to three times for 15 minutes each with 2 X SSC, 0.1 to 0.2% SDS at 55°C. For example, “medium-high stringency conditions” can be prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms / ml of sheared and denatured salmon sperm DNA, and 35% formamide for 12-24 hours, for a probe of at least 100 nucleotides in length, according to standard Southern blotting procedures. The carrier material can be finally washed two to three times for 15 minutes each with 1 to 2 X SSC, 0.1 to 0.2% SDS at 60°C.
[0506] For example, “high stringency conditions” can be prehybridization and hybridization at 42°C in 5 X SSPE, 0.3% SDS, 200 micrograms / ml of sheared and denatured salmon sperm DNA, and 35% formamide for 12-24 hours, for a probe of at least 100 nucleotides in length, according to standard Southern blotting procedures. The carrier material can be finally washed two to three times for 15 minutes each with 2 X SSC, 0.1 to 0.2% SDS at 65°C.
[0507]
[0508] The "nucleic acid construct" provided in the present application comprises a polynucleotide encoding a polypeptide provided in the present application, operably linked to one or more regulatory sequences that direct expression of the coding sequence in a suitable host cell under conditions suitable for the regulatory sequences.
[0509] Polynucleotides can be manipulated in a variety of ways to enable polypeptide expression. Depending on the expression vector, it may be desirable or necessary to manipulate the polynucleotide before inserting it into the vector. Such manipulations can be performed using methods known in the art.
[0510]
[0511] The "vector" provided in this application refers to a DNA construct containing a base sequence of a polynucleotide encoding the polypeptide of the present application, operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the polypeptide of the present application in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector can replicate or function independently of the host genome, and can be integrated into the genome itself.
[0512] The vector that can be used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors can be used.
[0513] For example, a polynucleotide encoding a polypeptide provided in the present application can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0514]
[0515] The “host cell” of the present application may include, without limitation, any cell capable of expressing the polypeptide of the present application.
[0516] The host cell of the present application may comprise the above-described polypeptide, a polynucleotide encoding the polypeptide, a nucleic acid construct comprising the same, and / or a vector.
[0517] The nucleic acid construct or vector may be integrated into a chromosome as described above, or may be maintained as an extrachromosomal vector that replicates autonomously.
[0518] The host cell of the present invention includes any progeny of the parent cell that are not identical to the parent cell due to mutations that occur during replication.
[0519] The host cell can be any cell useful for recombinant production of a polypeptide, e.g., a prokaryotic or eukaryotic cell.
[0520] The prokaryotic host cell can be any gram-positive or gram-negative bacterium.
[0521] Gram-positive bacteria include, but are not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, Corynebacterium, and Streptomyces.
[0522] Gram-negative bacteria include, but are not limited to, Campylobacter, Escherichia, Flavobacterium, Fusobacterium, Helicobacter, Iliobacter, Neisseria, Pseudomonas, Salmonella, Vibrio (e.g., Vibrio natriegens), and Ureaplasma.
[0523] In one specific example, the bacterial host cell can be a Bacillus genus host cell, specifically including but not limited to Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis and Bacillus thuringiensis cells.
[0524] In one specific example, the bacterial host cell can be a Streptococcus genus host cell, specifically including but not limited to Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis and Streptococcus equi subspecies Zooepidemicus cells.
[0525] In one specific example, the bacterial host cell can be a host cell of the genus Streptomyces, specifically including but not limited to Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicol, Streptomyces griseus and Streptomyces lividans cells.
[0526] In one specific example, the bacterial host cell may be a host cell of the genus Corynebacterium, such as Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium stationis, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes. ammoniagenes), Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens.
[0527] In one specific example, the bacterial host cell may be a host cell of the genus Escherichia, such as, but not limited to, Escherichia coli (E. coli).
[0528] The host cell may be a eukaryote, such as a mammalian, insect, plant, or fungal cell.
[0529] The host cell may be a fungal cell. In the present application, "fungus" includes the Ascomycota, Basidiomycota, Fasciomycota, and Zygomycota, as well as the Oomycota and all imperfect fungi.
[0530] The fungal host cell may be a yeast cell. The term "yeast" in the present application includes yeasts belonging to the order ascosporogenous yeasts (Endomycetales), basidiosporogenous yeasts, and Fungi imperfecti (Blastomycetes). However, this classification may vary and may be defined according to the Biology and Activities of Yeast (Skinner, Passmore, and Davenport, editors, Soc. App. Bacteriol. Symposium Series No. 9, 1980).
[0531] The yeast host cell is a Candida, Hansenula, Kluyveromyces, Pichia, Komagataella, Saccharomyces, Schizosaccharomyces or Yarrowia cell, for example, Kluyveromyces lactis, Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces These may be cells of Saccharomyces norbensis, Saccharomyces oviformis, Komagataella phaffii or Yarrowia lipolytica.
[0532] The fungal host cell may be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the phylum Eumycota and the subphylum Oomycota (as defined in the above reference (Hawksworth et al., 1995)). Filamentous fungi are typically characterized by a hyphal wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation, and carbonation is strictly aerobic. In contrast, vegetative growth in yeasts, such as Saccharomyces cerevisiae, is by germination of a unicellular thallus, and carbonation may be fermentative.
[0533] The filamentous fungal host cells are Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Mycellioptora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, It may be a cell of Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes or Trichoderma.
[0534] For example, the filamentous fungal host cells include Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis Ceriporiopsis subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense,Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei, Mysellioptora thermophila, Neurospora crassa, Penicillium purpurogenum, Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichoderma Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum,It may be a cell of Trichoderma reesei or Trichoderma viride, but is not limited thereto.
[0535]
[0536] The “composition” of the present application may comprise a polypeptide having PET decomposition activity, or a host cell expressing the polypeptide.
[0537] The above-described content regarding the polypeptide having PET decomposition activity or the host cell expressing the polypeptide provided in the present application may be applied.
[0538] The composition of the present application can be used to convert polyester into a final product.
[0539] The term "polyester" refers to a polymer that contains an ester functional group in the main chain of its structure. For example, polyethylene terephthalate is a semi-aromatic copolymer composed of two monomers, terephthalic acid and ethylene glycol (EG).
[0540] The polyester may be selected from polyethylene terephthalate (PET), polyethylene terephthalate glycol (PETG), polyethylene co-isosorbide-terephthalate (PEIT), polytrimethylene terephthalate (PTT), polybutylene adipate terephthalate (PBAT), polycyclohexylenedimethylene terephthalate (PCT), and polybutylene terephthalate (PBT). Specifically, the polyester may be PET.
[0541] The polypeptide of the present invention or a composition comprising the same can be used to depolymerize PET into bis(2-hydroxyethyl) terephthalate (BHET), or to decompose PET into mono(2-hydroxyethyl) terephthalate (MHET) and terephthalic acid (TPA).
[0542] The polypeptide of the present invention or a composition comprising the same can be used to degrade polymers (e.g., oligomers) derived from PET depolymerization. For example, it can be used to degrade BHET into MHET and TPA.
[0543]
[0544] The composition of the present application may further comprise other components in addition to the polypeptide having PET decomposition activity provided in the present application. Those skilled in the art can appropriately select the components to be added to the composition of the present application.
[0545] In one specific example, the composition of the present application may further comprise any component suitable for application in converting PET into a final product.
[0546] In one specific example, the composition of the present application may further comprise any component suitable for application to PET degradation.
[0547] Examples of substances that may be added include, but are not limited to, stabilizers, surfactants, builders, chelating agents, dispersants, enzymes, enzyme stabilizers, catalysts, activators, carriers, compounding agents, lubricants, disintegrants, excipients, solubilizers, suspending agents, colorants, flavorings, buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, diluents, lubricants, preservatives, and the like.
[0548] In one specific example, the composition provided in the present application may further include a naturally occurring substance or a non-naturally occurring substance in addition to the polypeptide provided in the present application.
[0549] In one specific example, the composition provided in the present application may further comprise an additional enzyme in addition to the polypeptide provided in the present application.
[0550]
[0551] A method for producing a polypeptide of the present invention may include a step of culturing a host cell; and a step of recovering a polypeptide expressed in the culturing step.
[0552] In this application, the term "cultivation" refers to growing the host cells under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the culturing process may be batch, continuous, or fed-batch, but is not limited thereto.
[0553] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the host cells, and supplies nutrients and growth factors, including water, which is essential for survival and development. Specifically, the medium and other culture conditions used for culturing the host cells of the present application may be any medium used for culturing conventional host cells without particular limitation, but the host cells of the present application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a conventional medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin.
[0554] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted into reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0555] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0556] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0557] In addition, during the cultivation of the host cells, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. can be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming can be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas can be injected into the medium, or in order to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas can be injected without injecting gas, but is not limited thereto.
[0558] The temperature of the medium may be, but is not limited to, 20°C to 50°C, specifically 25°C to 40°C. The incubation period may continue until the desired amount of useful material is obtained, specifically 24 hours to 196 hours, but is not limited thereto.
[0559]
[0560] In one specific example, the polypeptide expressed in the above-described culturing step can be recovered using methods known in the art. For example, the polypeptide can be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.
[0561] The above recovery method may be to collect the polypeptide using a suitable method known in the art according to the culture method of the host cell of the present application, for example, a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallization protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC and a combination of these methods may be used, and the polypeptide may be recovered from the medium or host cells using a suitable method known in the art.
[0562] In another specific embodiment, the polypeptide expressed by the host cell during the culture step may not be recovered. In this specific embodiment, the host cell expressing the polypeptide itself may be used as a source of the polypeptide.
[0563]
[0564] The present application may include a method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA) and / or ethylene glycol (EG) comprising contacting a polyester with a polypeptide having PET degrading activity as described above or a host cell expressing the polypeptide or a composition comprising the same.
[0565] Specifically, polyester may include the above-mentioned content.
[0566] In the present application, the term "contacting" a polyester with a polypeptide having PET degrading activity, a host cell expressing the polypeptide, or a composition comprising the same, means, but is not limited to, degrading the polyester. Degradation may also be used as depolymerization.
[0567] The time required to degrade polyester can vary depending on several process parameters (e.g., temperature, pH, additional chemicals, etc.), as well as the nature and origin of the polyester-containing article itself (i.e., the properties and origin of the plastic article, its composition, shape, etc.), the form and amount of the polypeptide having PET degrading activity used, etc. The process parameters can be readily adapted to the article containing polyester using techniques known in the art.
[0568] For example, the degradation process may be carried out at a temperature of from 20° C. to 90° C., preferably from 40° C. to 80° C., and more preferably from 50° C. to 70° C. More specifically, the temperature may be maintained below an inactivation temperature corresponding to the temperature at which the polypeptide is inactivated and / or below a temperature at which the host cell no longer synthesizes the polypeptide.
[0569] For example, the decomposition process can be carried out at pH 5 to pH 11, and preferably at pH 6 to pH 9.
[0570] As a specific example in the present application, an article comprising polyester may be pretreated prior to contact with the polypeptide having the PET decomposition activity of the present invention to physically or chemically modify its structure, thereby increasing the area of contact with the polypeptide.
[0571] Specifically, MHET, TPA and / or EG that may result from decomposition by the above contact can be recovered sequentially or continuously.
[0572] Specifically, the recovered MHET, TPA and / or EG can be further purified using any suitable purification method and produced in a re-polymerizable form. More preferably, the purification may include, but is not limited to, a stripping process, separation by aqueous solution, steam selective condensation, filtration and concentration of the post-biological process medium, separation, distillation, vacuum evaporation, extraction, electrodialysis, absorption, ion exchange, precipitation, crystallization, concentration and acid addition dehydration and precipitation, nanofiltration, acid catalyzed treatment, semi-continuous mode distillation or continuous mode distillation, solvent extraction, evaporative concentration, evaporative crystallization, liquid / liquid extraction, hydrogenation, an azeotropic distillation process, absorption, column chromatography, simple vacuum distillation and microfiltration.
[0573]
[0574] The final products MHET, TPA, and / or EG obtained using the composition of the present application can be reused for polymerization of polyester.
[0575] Specifically, the obtained final products, MHET, TPA, and / or EG, can be reused as repolymerizable monomers and / or oligomers to synthesize polyesters. Specifically, polyesters with the same properties can be repolymerized and, by mixing with other monomers and / or oligomers, can be synthesized, for example, into new copolymers.
[0576] The polyester may be selected from polyethylene terephthalate (PET), polyethylene terephthalate glycol (PETG), polyethylene co-isosorbide-terephthalate (PEIT), polytrimethylene terephthalate (PTT), polybutylene adipate terephthalate (PBAT), polycyclohexylenedimethylene terephthalate (PCT), and polybutylene terephthalate (PBT). Specifically, the polyester may be PET.
[0577] Methods for synthesizing polyesters using MHET, TPA, and / or EG are known in the art.
[0578]
[0579] Example
[0580] Hereinafter, this application will be described in more detail through examples and experimental examples. However, these examples and experimental examples are intended to exemplify this application and the scope of this application is not limited to these examples and experimental examples.
[0581]
[0582] Example 1. Derivation of PET degrading enzyme candidates from the NCBI database.
[0583] To identify novel PET-degrading enzymes, we performed a PSI-BLAST search using default parameters against 20 seeds known to have PET-degrading activity in Genbank Release 235 (Dec 15, 2019, https: / / www.ncbi.nlm.nih.gov / genbank / release / ) and a non-redundant database based on RefSeq, and fused the resulting sequence lists. The 20 seed sequences are summarized in Table 1.
[0584]
[0585] 씨드 (seed) 서열GenbankPSI-BLAST cutoffHit seqsThh_EstAFA451221.00E-401804Est1BA1992301.00E-232082Est2BAK485901.00E-401891Thc_Cut2ADV925277.00E-252008TfCut2CBY055302.00E-222080Thc_Cut1ADV925264.00E-371936Tfu_0882AAZ549205.00E-242044Thf42_Cut1ADV925283.00E-341911TfCut1CBY055296.00E-361926TfHAAZ549215.00E-421858BTA2CAH175545.00E-331961Cut190SFP436952.00E-331950Tcur0390ACY959911.00E-301956Tcur1278ACY968611.00E-291953LCCAEV212615.00E-341894PETaseGAP383732.00E-351924PET12AKJ291643.00E-361939PET6WP_0210188941.00E-301874PET5CCK749721.00E-281961LIPLAF5-2ACC952083.00E-341912
[0586]
[0587] Among the 2103 sequences obtained by the above method, 39 sequences considered to be partial genes (incomplete sequences) were excluded, resulting in a total of 2064 sequences. A k-tuple pairwise distance (Wilbur and Lipman, 0~1) matrix was generated, and a sequence similarity network was generated through a 0.3 distance cutoff. (Wilbur WJ, Lipman DJ. Rapid similarity searches of nucleic acid and protein data banks. Proc Natl Acad Sci US A. 1983 Feb;80(3):726-30.) A sequence representing each cluster was secured, resulting in a total of 152 sequences. The actual PET degradation activity and its strength of the above enzymes were confirmed in Examples 2 and 3.
[0588]
[0589] Example 2. Preparation of enzyme for analysis of plastic degradation activity.
[0590] In order to confirm the PET degradation activity of the PET degradation enzyme candidate derived from Example 1, an experiment was conducted as follows. 152 genes of Example 1 codon-optimized for E. coli were synthesized and amplified through polymerase chain reaction (PCR). The nucleotide sequence corresponding to the signal peptide was removed from the synthesized DNA. Thereafter, the PCR product was subcloned into the pET22b(+) (Novagen) vector, which does not have its own signal peptide. The E. coli BL21(DE3)-T1R strain was transformed with the generated expression vector pET22b(+). The E. coli strain was cultured in a flask containing 1 L of lysogeny broth medium containing 200 mg / L ampicillin at 37°C to an optical density at 600 nm of 0.6. Protein expression was induced by the addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and the culture medium was further incubated at 18°C for 16 h. Cells were then harvested by centrifugation at 4000 × g for 20 min at 4°C. The cell pellet was resuspended in buffer A (50 mM Na2HPO4-HCl, pH 7.0) and disrupted by sonication. Cell debris was removed by centrifugation at 13500 × g for 25 min, and the supernatant was applied to a Ni-NTA agarose column (Qiagen). After washing with buffer A containing 30 mM imidazole, bound proteins were eluted with 300 mM imidazole in buffer A.Finally, trace contaminants were removed by size-exclusion chromatography using a Superdex 200 prepgrade column (320 ㎖, GE Healthcare) equilibrated with buffer A. All purification steps were performed at 4°C. Protein purity was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The purified protein was concentrated in 50 mM Na2HPO4-HCl (pH 7.0) and 100 mM NaCl.
[0591]
[0592] Example 3. Analysis of PET degradation activity of manufactured PET degradation enzyme candidates
[0593] To analyze the PET degradation activity of the PET-degrading enzyme candidate manufactured in Example 2, 15 mg of PET bottle powder (B-PET) was prepared and immersed in 1 mL of 50 mM Glycine-NaOH (pH 9.0) buffer together with 500 nM enzyme. B-PET (PET sample derived from PET bottles) was obtained through the following processing. Transparent PET bottles were crushed using a crusher, and the crushed PET was melted in a high-temperature oven at 270°C. The molten PET was immediately immersed in 4°C water to harden. The obtained cured PET was subjected to a cryogenic grinding process and then passed through a steel mesh to obtain PET powder of 300 μm or less. The reaction mixture was reacted at 30°C for 12 hours. The reaction mixture was then analyzed using HPLC. MHET and TPA generated after the reaction were analyzed using HPLC to evaluate the PET degradation activity. The buffer of Example 2 used for purifying the enzyme as a control group was added and the reaction was performed, and the PET decomposition activity of 152 enzymes in the experimental group was evaluated and shown in Table 2.
[0594] Accession codePET분해산물농도 (uM)Accession codePET분해산물농도 (uM)대조군0.0WP_084400763.146.3SDZ16714.11506.2ADV92527.144.1SHM40309.1991.7WP_014689902.143.8WP_117215036.1953.4WP_093935592.138.3WP_084434874.1739.2RZS34008.136.3WP_116180173.1703.5WP_138709315.134.4WP_109362551.1694.3WP_141569747.134.0WP_091553551.1627.51JFR_A33.9WP_132413760.1614.4WP_124770494.131.5OGB27210.1610.94WFI_A30.5WP_101366623.1593.3WP_143737449.128.7WP_124822775.1577.6CBY05529.125.7WP_110567505.1548.1WP_111700265.124.4WP_054022242.1525.3WP_143320421.123.7WP_130464304.1483.4WP_084578793.123.0WP_073887759.1466.6WP_104613137.122.4WP_088988822.1463.2WP_104115406.120.1WP_082377728.1432.6SPF04022.119.1WP_132386942.1432.3WP_119701604.119.0CCH19814.1426.5WP_120326365.116.7WP_039906502.1426.5PWW60275.115.5WP_132337032.1399.5WP_086668955.115.3PIG53436.1385.4WP_092528534.114.3WP_082403176.1358.6WP_150303381.113.2WP_137976057.1355.5WP_063729606.111.8WP_085749752.1342.43VIS_A10.8WP_125191182.1337.2WP_138698985.110.5WP_141984372.1333.8WP_145923095.110.0WP_155388305.1310.5WP_068752972.19.6WP_013736455.1291.3MBA55398.19.4WP_143590710.1287.9WP_123888242.18.8WP_139584963.1271.5WP_088276085.18.7WP_078759821.1269.2WP_083724990.18.6AEV21261.1262.5WP_044499735.18.0WP_083950838.1256.8WP_051808300.17.4KWV31814.1250.0WP_067035690.17.0ADV92525.1248.2WP_103564314.17.0OKK16161.1243.9WP_080048780.16.9WP_013229249.1234.6WP_129849678.15.7WP_131056699.1231.4WP_125627453.15.0WP_045318561.1213.8WP_083947829.14.8WP_047194864.1208.9WP_083303042.14.6WP_072476921.1200.9KOV66859.14.2WP_075737041.1200.1SDH02982.13.9WP_065917710.1198.5PKM30861.13.8WP_130401777.1192.1WP_103939557.13.8WP_081971423.1191.2WP_120781673.13.6WP_093411427.1188.0WP_143713288.13.1WP_086849962.1186.8WP_136529585.12.9WP_109639600.1179.4WP_091310325.12.8WP_076469402.1157.7GAP50618.12.5WP_086784246.1130.9WP_020639922.12.5WP_080041749.1128.4SCF11721.12.5WP_125313231.1124.4KJK32958.12.4WP_120675340.1118.1WP_130477875.12.2WP_027346283.1114.2WP_105645204.12.1WP_155541557.1113.6KWV30420.12.1WP_075975245.1110.9WP_107417268.11.8WP_144126986.1110.1EOD65379.11.7 WP_078844206.1109.9WP_092287378.11.6WP_091283529.1104.6WP_122982115.11.5WP_1035034 99.1104.3WP_107115530.11.4WP_130969140.1103.0PWK87198.11.4WP_112669767.199.8KYG520 38.11.3KNX38636.189.0ALD14029.11.3GBD22443.187.9OUE26840.11.3WP_083302694.187.8WP_ 132628273.11.3WP_091084084.187.5WP_052685689.11.2WP_132183354.178.5SBV25448.11.2WP _093954453.178.1MAM88718.11.2WP_116813002.170.2WP_146103553.11.1WP_089021493.168.4 RZI82703.11.0PWK39581.164.8RZL00883.10.7WP_011291330.158.8WP_148029222.10.6WP_1236 85830.153.0WP_108710096.10.5WP_123748612.149.7WP_132200424.10.1WP_106966793.10.02.
[0595]
[0596] Example 4. Domain analysis of 152 sequences with confirmed PET degradation activity.
[0597] To search for the Conserved Domain associated with PET degradation activity, the amino acid sequences of 152 genes confirmed to have PET degradation activity were searched against the NCBI Conserved Domain Database (Lu S, Wang J, Chitsaz F, Derbyshire MK, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI, Marchler GH, Song JS, Thanki N, Yamashita RA, Yang M, Zhang D, Zheng C, Lanczycki CJ, Marchler-Bauer A. CDD / SPARCLE: the conserved domain database in 2020. Nucleic Acids Res. 2020 Jan 8;48(D1):D265-D268. doi: 10.1093 / nar / gkz991. Epub 2019 Nov 28. [PubMed PMID: 31777944]) containing 63,113 Conserved Domain Profiles. The Reverse Position-Specific BLAST program (rpsblast,]http: / www.ncbi.nlm.nih.gov / Structure / cdd / wrpsb.cgi) was run with default options, and it was confirmed that 152 genes were aligned with the COG4188 profile with an e-value of less than 10. Multiple sequence alignment between the amino acid sequences of the 152 genes and the COG4188 consensus sequence (https: / ncbi.nlm.nih.gov / Structure / cdd / cdd_help.shtml#CDConsensus) was performed using clustalw2 (Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG.(2007).Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947-2948.) were used with default options. Since the lengths of the 152 gene sequences were different, the location of the COG4188 consensus sequence was used as the representative location in the Multiple Sequence Alignment results. The aligned amino acid frequencies at each position of the COG4188 consensus sequence were calculated based on the BLOSUM62 matrix (Mark P Styczynski; Kyle L Jensen; Isidore Rigoutsos; Gregory Stephanopoulos (2008). "BLOSUM62 miscalculations improve search performance". Nat. Biotechnol. 26 (3): 274-275. doi:10.1038 / nbt0308-274. PMID 18327232. S2CID 205266180.) used as the default in NCBI BLAST. As a result, common mutations at 10 positions and conserved sequences at 14 positions were identified compared to the COG4188 consensus sequence. Information on conserved regions was expressed using the PROSITE Pattern (https: / prosite.expasy.org / prosuser.html) notation. In the PROSITE Pattern, '[ ]' represents one or more amino acids corresponding to a specific position, for example, [ALT] represents Ala or Leu or Thr. The 10 common mutation positions and 14 conserved sequence positions are as follows.
[0598] - 10 mutation information
[0599] G62[FWY], L70P, G81[ILMV], T85P, G113[DNE], Y118[RQK], D135[QREK], Q304[HNY], L322[WFY], A330[DNE]
[0600] -14 identical information
[0601] G86, [LIMV]94, [AS]95, [AS]96, G98, [FWY]99, [VILM]100, [VILM]101, [DNE]157, G165, [SANT]167, G169, G170, [DNE]262
[0602]
[0603] Example 5. Analysis of amino acid similarity among 152 sequences with confirmed PET degradation activity.
[0604] A sequence similarity analysis was performed on the 152 sequences obtained through Example 1. The similarity between sequences was performed using fasta36 (WR Pearson & DJ Lipman PNAS (1988) 85:2444-2448) with the default options. As a result of the similarity analysis between PET degradation activity genes, when WP_039906502.1 of sequence number 2 was used as a sample for amino acid similarity analysis, 20 amino acid sequences with a similarity of 80% or more (minimum 82.2% identity) were identified, which shows that the sequence with the highest level of commonality among the 152 sequences is WP_039906502.1. The Accession Numbers of sequences showing a similarity of 80% or more are as follows. CCH19814.1, WP_110567505.1, WP_112669767.1, WP_124822775.1, WP_089021493.1, WP_139584963.1, WP_130401777.1, PIG53436.1, WP_088988822.1, WP_082377728.1, WP_091553551.1, WP_101366623.1, WP_124770494.1, KWV31814.1, WP_083302694.1, WP_091283529.1, WP_093411427.1, WP_131056699.1, WP_013736455.1, WP_130464304.1
[0605]
[0606] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
Claims
1. A step of preparing an amino acid sequence of a polypeptide (predicted polypeptide) expected to have PET decomposition activity; A step of aligning the amino acid sequence of the predicted polypeptide based on the reference sequence of sequence number 1, and A method for identifying a polypeptide having PET decomposition activity, comprising a step of confirming whether the amino acid sequence of the predicted polypeptide from the above alignment results has the following characteristics; Based on the reference sequence, sequence number 1, (1) The residue corresponding to position 62 is F, W or Y; (2) The residue corresponding to position 70 is P; (3) The residue corresponding to position 81 is I, L, M or V; (4) The residue corresponding to position 85 is P; (5) The residue corresponding to position 86 is G; (6) The residue corresponding to position 94 is I, L, M or V; (7) The residue corresponding to position 95 is A or S; (8) The residue corresponding to position 96 is A or S; (9) The residue corresponding to position 98 is G; (10) The residue corresponding to position 99 is F, W or Y; (11) The residue corresponding to position 100 is V, L, I or M; (12) The residue corresponding to position 101 is V, L, I or M; (13) The residue corresponding to position 113 is D, N or E; (14) The residue corresponding to position 118 is R, Q or K; (15) The residue corresponding to position 135 is Q, R, E or K; (16) The residue corresponding to position 157 is D, N or E; (17) The residue corresponding to position 165 is G; (18) The residue corresponding to position 167 is S, A, N or T; (19) The residue corresponding to position 169 is G; (20) The residue corresponding to position 170 is G; (21) The residue corresponding to position 262 is D, N or E. (22) The residue corresponding to position 304 is H, N or Y; (23) The residue corresponding to position 322 is W, F or Y; and (24) The residue corresponding to position 330 is D, N or E.
2. A method for identifying a polypeptide having PET decomposition activity, wherein the amino acid sequence of the predicted polypeptide is multiple in number.
3. It has PET decomposition activity, and based on the reference sequence, sequence number 1, (1) The residue corresponding to position 62 is F, W or Y; (2) The residue corresponding to position 70 is P; (3) The residue corresponding to position 81 is I, L, M or V; (4) The residue corresponding to position 85 is P; (5) The residue corresponding to position 86 is G; (6) The residue corresponding to position 94 is I, L, M or V; (7) The residue corresponding to position 95 is A or S; (8) The residue corresponding to position 96 is A or S; (9) The residue corresponding to position 98 is G; (10) The residue corresponding to position 99 is F, W or Y; (11) The residue corresponding to position 100 is V, L, I or M; (12) The residue corresponding to position 101 is V, L, I or M; (13) The residue corresponding to position 113 is D, N or E; (14) The residue corresponding to position 118 is R, Q or K; (15) The residue corresponding to position 135 is Q, R, E or K; (16) The residue corresponding to position 157 is D, N or E; (17) The residue corresponding to position 165 is G; (18) The residue corresponding to position 167 is S, A, N or T; (19) The residue corresponding to position 169 is G; (20) The residue corresponding to position 170 is G; (21) The residue corresponding to position 262 is D, N or E. (22) The residue corresponding to position 304 is H, N or Y; (23) The residue corresponding to position 322 is W, F or Y; and (24) The residue corresponding to position 330 is D, N, or E. A polypeptide comprising an amino acid sequence.
4. In the third paragraph, the polypeptide having the PET decomposition activity comprises a motif of the following general formulae 1 to 5: (General formula 1) X1-X2-X3-X4-X5-X6-X7-X8-P: where X1 is F, W, or Y; and X2 to X8 are any amino acid or absent; (General formula 2) X1-X2-X3-X4-PG: where X1 is I, L, M or V; and X2 to X4 are any amino acid or absent; (General formula 3) X1-X2-X3-X4-G-X5-X6-X7: X1 is I, L, M or V; X2 is A or S; X3 is A or S; X4 is any amino acid or absent; X5 is F, W or Y; X6 is V, L, I or M; and X7 is V, L, I or M; (General formula 4) X1-X2-X3-X4-X5-X6-X7-X8-G-X9-X10-X11-GG Here, X1 is D, N or E; X2 to X8, X9 and X11 are any amino acid or absent; and X10 is S, A, N or T; (General Formula 5) X1-X2-X3-X4-X5-X6-X7-X8-X9 Here, X1 is W, F or Y; X2 to X8 are any amino acid or absent; and X9 is D, N or E. 5.제1항에 있어서, 상기 폴리펩티드는 WP_109362551.1, SHM40309.1, SDZ16714.1, WP_084434874.1, WP_101366623.1, WP_117215036.1, WP_132413760.1, WP_110567505.1, WP_143590710.1, WP_091553551.1, WP_124822775.1, WP_116180173.1, OGB27210.1, WP_088988822.1, WP_125191182.1, WP_085749752.1, WP_130464304.1, WP_054022242.1, WP_082377728.1, WP_132386942.1, WP_082403176.1, WP_013736455.1, WP_073887759.1, CCH19814.1, WP_141984372.1, WP_155388305.1, WP_039906502.1, WP_137976057.1, WP_132337032.1, WP_093411427.1, WP_075737041.1, WP_139584963.1, WP_088276085.1, PIG53436.1, WP_045318561.1, WP_078759821.1, AEV21261.1, WP_047194864.1, WP_083950838.1, KWV31814.1, ADV92525.1, EOD65379.1, WP_013229249.1, WP_131056699.1, WP_072476921.1, WP_065917710.1, WP_130401777.1, WP_081971423.1, WP_086849962.1, WP_109639600.1, WP_150303381.1, WP_076469402.1, WP_086784246.1, WP_125313231.1, WP_120675340.1, WP_027346283.1, WP_155541557.1, WP_075975245.1, WP_144126986.1, WP_078844206.1, WP_091283529.1, WP_103503499.1, WP_130969140.1, WP_112669767.1, KNX38636.1, GBD22443.1, WP_083302694.1, WP_091084084.1, WP_093954453.1, WP_116813002.1, WP_089021493.1, PWK39581.1, WP_011291330.1, WP_123685830.1, WP_123748612.1, WP_084400763.1, WP_132183354.1, ADV92527.1, WP_014689902.1, WP_093935592.1, RZS34008.1, WP_138709315.1, WP_141569747.1, 1JFR_A, WP_124770494.1, 4WFI_A, WP_143737449.1, WP_080041749.1, CBY05529.1, WP_111700265.1, OKK16161.1, WP_143320421.1, WP_084578793.1, WP_104613137.1, WP_104115406.1, SPF04022.1, WP_119701604.1, WP_120326365.1, PWW60275.1, WP_086668955.1, WP_092528534.1, WP_063729606.1, 3VIS_A, WP_138698985.1, WP_145923095.1, WP_068752972.1, MBA55398.1, WP_123888242.1, WP_083724990.1, WP_044499735.1, WP_051808300.1, WP_067035690.1, WP_103564314.1, WP_129849678.1, WP_125627453.1, WP_083947829.1, WP_083303042.1, KOV66859.1, SDH02982.1, PKM30861.1, WP_103939557.1, WP_120781673.1, WP_136529585.1, WP_091310325.1, GAP50618.1, SCF11721.1, WP_130477875.1, KWV30420.1, WP_143713288.1, WP_107417268.1, WP_106966793.1, WP_092287378.1, WP_080048780.1, WP_122982115.1, PWK87198.1, KYG52038.1, OUE26840.1, WP_052685689.1, SBV25448.1, MAM88718.1, RZI82703.1, WP_107115530.1, KJK32958.1, WP_146103553.1, WP_132628273.1, ALD14029.1, RZL00883.1, WP_148029222.1, WP_105645204.1, A polypeptide having an amino acid sequence selected from WP_108710096.1, WP_020639922.1 and WP_132200424.
1.
6. A composition comprising a polypeptide according to any one of claims 3 to 5.
7. In the 6th paragraph, the composition is a composition for PET decomposition.
8. A polynucleotide encoding a polypeptide of any one of claims 3 to 5.
9. A host cell comprising a polypeptide according to any one of claims 3 to 5; a polynucleotide encoding the polypeptide; a nucleic acid structure comprising the polynucleotide; and / or a vector comprising the polynucleotide or the nucleic acid structure.
10. A step of culturing the host cell of clause 9; and Comprising a step of recovering a polypeptide expressed in the above culturing step, A method for producing a polypeptide having PET decomposition activity.
11. A method for decomposing a polyester, comprising treating the polyester with at least one of the polypeptide of any one of claims 3 to 5; a host cell expressing the polypeptide; and a composition comprising the polypeptide.
12. A decomposition method according to claim 11, wherein the polyester is PET.
13. A method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA) and / or ethylene glycol (EG), comprising contacting at least one of the polypeptides of any one of claims 3 to 5; a host cell expressing the polypeptide; and a composition comprising the polypeptide with a polyester.
14. A method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG) in claim 13, wherein the polyester is PET.
15. A method for producing mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG), wherein the method further comprises a step of recovering the produced MHET, TPA, and / or EG.
16. A method for producing polyester, comprising a step of synthesizing polyester using MHET, TPA, and / or EG manufactured by the method of any one of claims 13 to 15.
17. A method for producing polyester according to claim 16, wherein the polyester is PET.
18. A polypeptide according to any one of claims 3 to 5, a host cell expressing the polypeptide, or Use of a composition comprising the above polypeptide for PET degradation.
19. Use of a polypeptide or a composition comprising a polypeptide according to any one of claims 3 to 5 for reaction with a polyester in the production of mono(2-hydroxymethyl) terephthalate (MHET), terephthalic acid (TPA), and / or ethylene glycol (EG).
Citation Information
Patent Citations
IsPETase variants
US10851355B2
Rubber composition and method for manufacturing rubber product using the same
KR102259323B1
Mutations for improving activity and thermostability of petase enzymes
WO2022076380A2
